Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification.

Takahashi D, Kojima M, Suzuki T, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Ikeda M, Nakatsura T, Ochiai A, Nagino M.

Sci Rep. 2018 Sep 3;8(1):13166. doi: 10.1038/s41598-018-31383-9.

2.

Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer.

Wang Q, Lou W, Di W, Wu X.

Int Immunopharmacol. 2017 Nov;52:7-14. doi: 10.1016/j.intimp.2017.08.017. Epub 2017 Aug 31.

PMID:
28846888
3.

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.

Lamarca A, Nonaka D, Breitwieser W, Ashton G, Barriuso J, McNamara MG, Moghadam S, Rogan J, Mansoor W, Hubner RA, Clark C, Chakrabarty B, Valle JW.

Oncotarget. 2018 Feb 12;9(19):14922-14938. doi: 10.18632/oncotarget.24464. eCollection 2018 Mar 13.

4.

Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.

Yang CY, Lin MW, Chang YL, Wu CT, Yang PC.

Eur J Cancer. 2016 Apr;57:91-103. doi: 10.1016/j.ejca.2015.12.033. Epub 2016 Feb 21.

PMID:
26901614
5.

Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.

Kim A, Lee SJ, Kim YK, Park WY, Park DY, Kim JY, Lee CH, Gong G, Huh GY, Choi KU.

Sci Rep. 2017 Sep 15;7(1):11671. doi: 10.1038/s41598-017-11905-7.

6.

Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma.

Shimizu K, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M.

Cancer Manag Res. 2017 Nov 30;9:741-750. doi: 10.2147/CMAR.S146897. eCollection 2017.

7.

Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology.

Han X, Xu X, Ma H, Ji Y, Wang D, Kuang T, Wu W, Song B, Li G, Jin G, Lou W.

Endocr Connect. 2018 Feb;7(2):355-363. doi: 10.1530/EC-17-0388.

8.

The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.

Bonanno L, Pavan A, Dieci MV, Di Liso E, Schiavon M, Comacchio G, Attili I, Pasello G, Calabrese F, Rea F, Favaretto A, Rugge M, Guarneri V, Fassan M, Conte PF.

Eur J Cancer. 2018 Sep;101:191-200. doi: 10.1016/j.ejca.2018.06.023. Epub 2018 Aug 1.

PMID:
30077124
9.

The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).

Tomioka N, Azuma M, Ikarashi M, Yamamoto M, Sato M, Watanabe KI, Yamashiro K, Takahashi M.

Breast Cancer. 2018 Jan;25(1):34-42. doi: 10.1007/s12282-017-0781-0. Epub 2017 May 9.

PMID:
28488168
10.
11.

Role of immune microenvironment in gastrointestinal stromal tumours.

Blakely AM, Matoso A, Patil PA, Taliano R, Machan JT, Miner TJ, Lombardo KA, Resnick MB, Wang LJ.

Histopathology. 2018 Feb;72(3):405-413. doi: 10.1111/his.13382. Epub 2017 Nov 21.

PMID:
28871595
12.

PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.

Ren M, Dai B, Kong YY, Lv JJ, Cai X.

Histopathology. 2018 Sep;73(3):386-396. doi: 10.1111/his.13527. Epub 2018 Jun 8.

PMID:
29637587
13.

Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.

Okabe M, Toh U, Iwakuma N, Saku S, Akashi M, Kimitsuki Y, Seki N, Kawahara A, Ogo E, Itoh K, Akagi Y.

Cancer Sci. 2017 Jan;108(1):81-90. doi: 10.1111/cas.13114. Epub 2017 Jan 21.

14.

Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.

Diana A, Wang LM, D'Costa Z, Allen P, Azad A, Silva MA, Soonawalla Z, Liu S, McKenna WG, Muschel RJ, Fokas E.

Oncotarget. 2016 Jul 5;7(27):40992-41004. doi: 10.18632/oncotarget.10038.

15.

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Jöhrens K.

Oncotarget. 2016 Jan 12;7(2):1486-99. doi: 10.18632/oncotarget.6429.

16.

Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer.

Ju X, Shen R, Huang P, Zhai J, Qian X, Wang Q, Chen M.

Oncotarget. 2017 Oct 26;8(59):99372-99381. doi: 10.18632/oncotarget.22079. eCollection 2017 Nov 21.

17.

Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.

Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II.

Clin Cancer Res. 2016 Dec 15;22(24):6278-6289. Epub 2016 Jun 1.

18.

Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.

Cavalcanti E, Armentano R, Valentini AM, Chieppa M, Caruso ML.

Cell Death Dis. 2017 Aug 24;8(8):e3004. doi: 10.1038/cddis.2017.401.

19.

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.

Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ.

Gut. 2017 May;66(5):794-801. doi: 10.1136/gutjnl-2015-310839. Epub 2016 Jan 22.

20.

Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer.

Fang W, Chen Y, Sheng J, Zhou T, Zhang Y, Zhan J, Liu L, Huang J, Peng P, Zhang L.

J Cancer. 2017 Jun 3;8(9):1579-1585. doi: 10.7150/jca.18729. eCollection 2017.

Supplemental Content

Support Center